| Document |
Document Title |
|
JP2015504054A |
The present invention comprises a phenylcarbamate compound, a pharmaceutical composition for the treatment and / or prevention of multiple sclerosis containing the phenylcarbamate compound as an effective component, and a therapeutic and...
|
|
JP5663154B2 |
Process for optical resolution of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile (I) comprises separating enriched racemic or enantiomeric mixture of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile into its two ena...
|
|
JP5662345B2 |
The present invention relates to a process for separating an enantiomer mixture of (R)- and (S)-3-amino-1-butanol optionally protected on the oxygen atom, and to a process for preparing essentially enantiomerically pure (R)-3-amino-1-but...
|
|
JP5656635B2 |
The present invention relates to the resolution by preferential crystallization of potassium salts of racemic omeprazole which is a solvate of ethanol and/or of ethylene glycol, which consists in converting the omeprazole to the potassiu...
|
|
JP2015003861A |
To easily and efficiently produce (R)-2-amino-2-ethylhexanol that is useful as a pharmaceutical intermediate without carrying out a complicated operation.(R)-2-amino-2-ethylhexanol is produced by subjecting a N-benzylidene-2-amino ester ...
|
|
JP5646606B2 |
Disclosed is an antitumor agent which has higher antitumor activity than conventional antitumor agents, while having low toxicity. Specifically disclosed is an antitumor agent which is characterized by containing a phosphine transition m...
|
|
JP5605008B2 |
|
|
JP5605716B2 |
Disclosed is a method for producing an optically active 2-hydroxy ester, comprising selectively esterifying one enantiomer of a racemic 2-hydroxy ester in a solvent containing a catalyst such as tetramisole or benzotetramisole, and a car...
|
|
JP5604520B2 |
The present invention relates to a compound of formula I, in all its isomeric forms and pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatm...
|
|
JP5603627B2 |
|
|
JP5603884B2 |
Embodiments are provided that provide for efficient production of highly pure natural I-menthol. In some embodiments, a method for preparing natural I-menthol involves providing crude mentha oil in a crystallizer and gradually reducing t...
|
|
JP5603626B2 |
|
|
JP5598330B2 |
The present invention is a simple method, in which a specific amount of alkali is added to an enantiomeric mixture of an optically active organic carboxylic acid where enantiomers are present in a non-equimolar ratio, or in which the ena...
|
|
JP5596134B2 |
The present invention relates to a resolution process of (±)-methyl phenyl[4-[4-[[[4'-(trifluoromethyl)-2-biphenylyl]carbonyl]am
ino]phenyl]-1-piperidinyl]acetate to isolate the MTP (microsomal triglyceride transfer protein) inhibitor m...
|
|
JP5595404B2 |
The present invention describes a novel process for the preparation of optically active (S)-(-)-2-(N-propylamino)-5-methoxytetraline and (S)-(-)-2-(N-propylamino)-5-hydroxytetraline compounds based on the optical resolution of mixtures o...
|
|
JP2014169252A |
To provide a new method of producing optically active β-formyl-β-hydroxy-α-substituted aldehyde compounds.A method of producing an optically active β-formyl-β-hydroxy-α-substituted aldehyde compound (2) includes the step of making ...
|
|
JP2014169294A |
To provide an optically active piperidine derivative which is excellent in antihistaminic activity and antiallergic activity, has little hygroscopicity and is excellent in physicochemical stability, and a manufacturing method thereof.Thi...
|
|
JP5585822B2 |
|
|
JP2014152156A |
To provide a method for obtaining an optically active material, when erythro ADPE or MA is used as a reagent for optical resolution, having a sign opposite to the previously obtained one without forming a diastereomeric salt again.To pro...
|
|
JP2014148531A |
To provide, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effe...
|
|
JP2014520126A |
The invention provides a new process for the preparation of solifenacin or a pharmaceutically acceptable acid addition salt thereof, comprising reacting (R)-quinuclidin-3-yl phenethylcarbamate with benzaldehyde in the presence of an acid...
|
|
JP5566103B2 |
The invention relates to a method for producing optically active 3-aminocarboxylic acid ester compounds. According to said method, an enantiomer mixture of a mono-N-acylated 3-aminocarboxylic acid ester, which mixture was previously enri...
|
|
JP5563830B2 |
The present invention relates to synthesis procedures and intermediates of a compound of formula: and the salts thereof.
|
|
JP2014133771A |
To provide processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity....
|
|
JP5553911B2 |
Provided is a process for preparing Voriconazole represented by Chemical Formula 1. More particularly, the process for preparing Voriconazole of Chemical Formula 1 includes: carrying out the Reformatsky-type coupling reaction between a k...
|
|
JP5557292B2 |
The problem to be solved is to provide a method for producing a compound having excellent activity as an ± 2 ´ ligand. The solution thereto is a method for producing a compound represented by the general formula (I) or a salt thereof b...
|
|
JP2014516920A |
Compounds of the formula (I) or salts thereof, in each case in the optically active (3R,4R)-threo form, in which R1 is hydrogen or a hydrolysable radical, and (R2)n, (R3)m, n and m are as defined in formula (I) according to claim 1, wher...
|
|
JP5552422B2 |
(6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid calcium salt aqueous solution production involves methylating (6S)-5,6,7,8-tetrahydrofolic acid with a part of the corresponding (6R)-diastereoisomer in the range of 4-8 wt.% in water. Calciu...
|
|
JP5544298B2 |
The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained durin...
|
|
JP5534460B2 |
|
|
JP5536869B2 |
A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.
|
|
JP5531097B2 |
The invention relates to improved processes for the preparation of ambrisentan. The invention also relates to new polymorphic form of ambrisentan. In particular, it relates to a polymorphic form, designated as Form I of ambrisentan and a...
|
|
JP5533654B2 |
|
|
JP5531288B2 |
Provided is a complex obtained by reacting a polymer compound derivative obtained by modifying part of hydroxy groups or amino groups of a polymer compound having the hydroxy groups or amino groups with a compound represented by the foll...
|
|
JP5520077B2 |
The present invention relates to a novel method for the preparation of diol intermediates useful for the preparation of escitalopram involving selective enzymatic acylation or deacylation.
|
|
JP5518337B2 |
A process for producing a labeled precursor which is useful for production of a radioactive fluorine-labeled amino acid compound is provided. In the reaction step for introducing a leaving group to a mixture of syn-form and anti-form of ...
|
|
JP5513621B2 |
The invention concerns a method for separating a racemic compound-forming chiral substance by a cyclic crystallization process which is conducted in at least one first crystallization unit (10) and in at least one second crystallization ...
|
|
JP5510040B2 |
|
|
JP5514549B2 |
The current invention describes a one-step process for the synthesis of 2-fluoropropionates from lactic acid ester derivatives using TFEDMA.
|
|
JP5503546B2 |
|
|
JP2014088389A |
To provide a diagnostic agent for positron emission tomography, comprising a [F-18]-labeled compound.A diagnostic agent for positron emission tomography (PET) comprises a compound which is a L-glutamic acid or L-glutamic acid derivative ...
|
|
JP5487440B2 |
The present invention relates to an improved process for the preparation of (R)-1-aminoindan (2), rasagiline (1) and pharmaceutically acceptable salts of rasagiline.
|
|
JP2014074033A |
To provide methods for isolating from a reaction mixture a salt of a mono-propargylated aminoindane (rasagiline), which is a selective inhibitor of MAO-B and useful in treating Parkinson's disease etc.Disclosed are production methods for...
|
|
JP5476859B2 |
|
|
JP2014509592A |
The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are...
|
|
JP5468003B2 |
Continuous process for the preparation of racemic or optically active menthol in a pure and enriched form, comprises distillative separation of racemic or optically active menthol from a material mixture containing racemic or optically a...
|
|
JP5456871B2 |
To provide a method for selectively producing (+)-cis-sertraline represented by formula 1 and usable as an intermediate in the production of sertraline hydrochloride.The method for producing the (+)-cis-sertraline represented by formula ...
|
|
JP5455394B2 |
|
|
JP5452165B2 |
Provided is a production method for a cis-QMF, which has a low environmental burden and is industrially advantageous. Specifically provided is a production method for a cis-type 2-alkylspiro(1,3-oxathiolane-5,3′)quinuclidine hydrochlor...
|
|
JP5451870B2 |
|
